International Symposium on Parkinson's disease


	The overarching goal of the Symposia of the Bordeaux Neurosciences Institute is to bring locally a selected set of top researchers on a scientific topic that is of broad interest to the community. There will be 2-3 symposia per year, with each symposium lasting 1 or 2 days. Symposia are open to everyone from Bordeaux and outside, and are free."

	International Symposium on New Therapeutic Avenues in Parkinson’s Disease and Related Disorders, Bordeaux, France, Bordeaux University, May 5 - 6 , 2010

	Organizers : Meissner, Tison and Bezard
	The objective of this meeting is to brainstorm and dialogue between international Parkinson’s disease experts and representatives of leading healthcare companies and innovative biotech startups, to better understand the evolution of the therapeutic area (met versus unmet needs, clinical trial design, derisking translational development, emerging treatment challenges) and its strategic implications for the Healthcare industry. The topics cover the most striking unmet treatment needs of our patients with the ambition to provide a cure for Parkinson’s disease in the future. Each expert will give an interactive presentation where he will briefly review his topic, define meaningful surrogate markers for the design of future clinical trials and identify the most promising and innovative treatment avenues

		Inscription fees vary from 0 to 150 euros according to your affiliation. To find out and to register, Registration , click


		Wednesday - May 5, 2010		Thursday - May 6, 2010

		9:00-9:30 Opening ceremony Manuel Tunon de Lara, President, University Victor Segalen Bordeaux 2 Alain Hériaud, General Director, University Hospital Bordeaux Jean-Marc Orgogozo, Chairman, Department of Clinical Neurosciences, University Hospital Bordeaux Morning Session (9:30-13:00) Chairmen Pierre Burbaud, Bordeaux, France 9:30-10:00 David Weiner, EMD Merck-Serono Inc, Rockland, MA, USA Challenges in the development of Parkinson's disease therapeutics, an industry perspective 10:30-11:00 Coffee Break 11:00-12:00 Andres Lozano, Toronto, Canada The potential of stereotactically-delivered treatments 12:00-13:00 Valerie Voon, Bethesda, MD, USA Emerging treatment challenges, the dopamine dysregulation syndrome 13:00-14:00 Lunch Break Afternoon Session (14:00-16:30) Chairmen Wassilios Meissner, Bordeaux, France 14:00-15:00 Anthony Schapira, London, UK How can we achieve neuroprotection in Parkinson’s disease: lessons from the past 15:00-16:00 Paola Piccini, London, UK Advances in functional neuroimaging for Parkinson's disease 16:00-16:15 Erwan Bezard, Bordeaux, France Presentation of the Bordeaux Institute for Neurodegenerative Disorders 16:15-16:45 Todd Sherer, Michael J Fox Foundation, New York, NY, USA The Michael J Fox Foundation		Morning Session (9:00-12:30) Chairmen Erwan Bezard, Bordeaux, France 9:00-10:00 François Tison, Bordeaux, France Parkinsonism and dementia: diagnosis and therapeutic challenges 10:00-11:00 Wassilios Meissner, Bordeaux, France How can we move on in atypical parkinsonism ? 11:00-11:30 Coffee Break 11:30-12:30 Christopher Goetz, Chicago, IL, USA Future treatments for dyskinesia: lessons from the past 12:30-13:30 Lunch Break Afternoon Session (13:30-17:30) Chairmen: François Tison, Bordeaux, France 13:30-14:30 Thomas Gasser, Tübingen, Germany Genetic dissection of Parkinson's disease as a basis for novel treatments ? 14:30-15:30 Jose Obeso, Pamplona, Spain Unresolved problems in the treatment of Parkinson’s disease 15:30-16:00 Coffee Break 16:00-17:00 Olivier Rascol, Toulouse, France Design of future clinical trials 17:00-17:30 Panel discussion: Conclusions from the Symposium Jose Obeso, Olivier Rascol and David Weiner 17:30 End of the Symposium